AMONG THE VARIOUS HORMONES produced by non-endocrine neoplasms, placental hormones (viz. human placental lactogen (hPL) and human chorionic gonadotrophin (hCG)) are of particular interest. Both hPL and hCG are produced by syncytiotrophoblast of the normal placenta, and are present in the circulation in large quantities during pregnancy. However, hCG has been detected in extracts of normal tissues, such as pituitary, testes, colon, liver and gastric epithelium (Braunstein et al., 1975; Vaitukaitis et al., 1976; Yoshimoto et al., 1977) . Similar reports are not available with regard to hPL, except for one study by Payne & Ryan (1971) , who showed the presence of hPL in apparently normal testes of a patient with carcinoma of the prostate. hPL is not known to be elaborated in various non-cancerous pathological conditions even at the low level of 2 pg/ml of serum (Weintraub & Rosen, 1971) . Secretions of hPL and hCG by carcinoma of the breast have been observed in our earlier studies (Sheth et al., 1974 (Sheth et al., , 1977 Midgley (1966) . All samples were run in duplicate using 200 and 400 pl of serum or tumour extract.
The assay was repeated twice to confirm the results. Samples were considered positive only when total precipitable counts were less than 80% of tubes with no antigen.
Studies on a total of 42 patients not harbouring any tumour but suffering from other diseases of the GI tract showed that serum hPL was undetectable in cases of duodenal ulcer (18), ulcerative colitis (6), gastritis (12), acute appendicitis (4), pancreatic pseudocyst (1) and tuberculosis of (Weintraub & Rosen, 1971; Rosen et al., 1975) . The higher incidence of hPL may be attributed to the highly sensitive and specific antiserum used in the present investigation. It may be noted that this antiserum showed no crossreactivity with hGH and hPRL. Also, false positive results were not observed when the same antiserum was used to examine sera from normal subjects or from those with non-neoplastic diseases of the GI tract. In addition, parallel curves observed with standard hPL and its ectopic counterpart indicated the immunological homology between these substances. In view of the high incidence of serum hPL in patients with tumours of the GI tract, and its undetectability in normal subjects and in non-neoplastic conditions, the possible use of hPL as a marker in cancer seems to be worth considering. The evidence that a hormone is a trulv ectopic product entails its demonstration in tumour tissue. The present study on 7 tumours shows that, whenever hPL was detected in serum it was also present in the tumour tissue, thus indicating that the placental peptide is a tumour-associated product. At the same time, the possibility of ectopic hormone being present in the tumour whilst it was undetectable in the circulation cannot be ruled out. Hence the tumours from 6 patients whose sera were hPL-were also examined. However, in the present study no such instance was detected; tumours were negative when sera were negative for hPL.
Postoperative sera from one patient with carcinoma of the stomach remained positive for hPL after excision of the tumour. It may be noted that this patient developed recurrence of the disease and died subsequently. Another interesting case was that of a patient with carcinoma of the rectum, whose serum level of hPL before radiotherapy was 2-5 ng/ml. However, after radiation therapy it was negative for hPL. It may be noted that this patient had an 18-month complete remission.
An interesting observation emerging from the present studies is that the tumour which did not show paraendocrine behaviour when checked earlier showed no hormone during the follow-up. It is therefore suggested that if the tumour has no ectopic secretion of hormone during its earlier stage, it will probably not acquire it during the later stages. This needs to be checked in a large number of cases. It appears that the secretion of hPL may not be confined to advanced stages of the disease, since the incidence of hPL secretion in the earlier stage is similar to that in the advanced stage. As tumours of the GI tract pose a unique problem in early detection owing to their anatomical situation and delayed appearance of symptoms, the evaluation of biochemical markers in patients suspected of such neoplasms is desirable.
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